Derek Galligan is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 23 publications with 264 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
100%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – The Oregon Health and Science University Experience
Clinical Lymphoma Myeloma & Leukemia
2023 - Long-Term Outcomes after Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – the Oregon Health and Science University Experience
Transplantation and Cellular Therapy
2022 - Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience
Clinical Lymphoma Myeloma & Leukemia
2021 - Second Autologous Stem Cell Transplant As Salvage in Multiple Myeloma – the Oregon Health and Science University Experience
Transplantation and Cellular Therapy
2021 - A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma
Leukemia & lymphoma/Leukemia and lymphoma
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Brian Druker, MD
Oregon Health & Science University
Kevin Winthrop, MD
Oregon Health & Science University
Richard Maziarz, MD
Oregon Health & Science University
Wayne Clark, MD
Oregon Health & Science University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”